EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cryotherapy for partial gland ablation of prostate cancer: Oncologic and safety outcomes

Mamdouh N Aker iD, Wayne G Brisbane, Lorna Kwan, Samantha Gonzalez, Alan M Priester, Adam Kinnaird, Merdie K Delfin, Ely Felker, Anthony E Sisk, David Kuppermann, Leonard S Marks

Cancer Medicine · 2023-04 · 12 (8) · 9351-9362

DOI: 10.1002/cam4.5692 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 12.02.2023. Verfasst von Mamdouh N Aker und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, David Geffen School of Medicine at University of California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, Jean Perkins Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Partial gland ablation (PGA) is a new option for treatment of prostate cancer (PCa). Cryotherapy, an early method of PGA, has had favorable evaluations, but few studies have employed a strict protocol using biopsy endpoints in men with clinically significant prostate cancer (csPCa).

Methods

143 men with unilateral csPCa were enrolled in a prospective, observational trial of outpatient PGA‐cryotherapy. Treatment was a 2‐cycle freeze of the affected prostate part. Participants were evaluated with MRI‐guided biopsy (MRGB) at baseline and at 6 months and 18 months after treatment. Absence of csPCa upon MRGB was the primary endpoint; quality‐of‐life at baseline and at 6 months after treatment was assessed by EPIC‐CP questionnaires in the domains of urinary and sexual function.

Results

Of the 143 participants, 136 (95%) completed MRGB at 6 months after treatment. In 103/136 (76%), the biopsy revealed no csPCa. Of the 103, 71 subsequently had an 18‐month comprehensive biopsy; of the 71 with 18‐month biopsies, 46 (65%) were found to have no csPCa. MRI lesions became undetectable in 96/130 (74%); declines in median serum PSA levels (6.9 to 2.5 ng/mL), PSA density (0.15 to 0.07), and prostate volume (42 to 34cc) were observed (all p < 0.01). Neither lesion disappearance on MRI nor PSA decline correlated with biopsy outcome. Urinary function was affected only slightly and sexual function moderately.

Conclusion

In the near to intermediate term, partial gland ablation with cryotherapy was found to be a safe and moderately effective treatment of intermediate‐risk prostate cancer. Eradication of cancer was better determined by MRI‐guided biopsy than by MRI or PSA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic NeoplasmsMaleHumansProspective StudiesCryotherapyImage-Guided BiopsyMagnetic Resonance Imaging

Stichwörter der Autor:innen

Prostate cancercryotherapyfocal therapy

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, David Geffen School of Medicine at University of California, Los Angeles, California, USA.
  • Avenda Health, Culver City, California, USA.
  • Department of Urology, University of Alberta, Edmonton, Alberta, USA.
  • Department of Radiology, David Geffen School of Medicine at University of California, Los Angeles.
  • Department of Pathology, David Geffen School of Medicine at University of California, Los Angeles, California, USA.

ORCID-Profile: Mamdouh N Aker

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • Jean Perkins Foundation
  • National Cancer Institute
  • Phase One Foundation
  • Prostate Cancer Foundation
  • Clinical and Translational Science Institute, University of California, Los Angeles

Zitieren

APA

Aker, M. N., Brisbane, W. G., Kwan, L., Gonzalez, S., Priester, A. M., Kinnaird, A., Delfin, M. K., Felker, E., Sisk, A. E., Kuppermann, D., & Marks, L. S. (2023). Cryotherapy for partial gland ablation of prostate cancer: Oncologic and safety outcomes. Cancer Medicine, 12(8), 9351-9362. https://doi.org/10.1002/cam4.5692

Vancouver

Aker MN, Brisbane WG, Kwan L, Gonzalez S, Priester AM, Kinnaird A, et al. Cryotherapy for partial gland ablation of prostate cancer: Oncologic and safety outcomes. Cancer Medicine. 2023;12(8):9351-9362. doi:10.1002/cam4.5692

BibTeX
@article{Aker2023,
  author = {Aker, Mamdouh N and Brisbane, Wayne G and Kwan, Lorna and Gonzalez, Samantha and Priester, Alan M and Kinnaird, Adam and Delfin, Merdie K and Felker, Ely and Sisk, Anthony E and Kuppermann, David and Marks, Leonard S},
  title = {Cryotherapy for partial gland ablation of prostate cancer: Oncologic and safety outcomes},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {8},
  pages = {9351--9362},
  doi = {10.1002/cam4.5692}
}
Kostenlos starten →